A Phase 3 interventional study of Nivolumab and Prednisone in Prostate Cancer, sponsored by Bristol-Myers Squibb. Completed at 293 sites in 28 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-12.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing nivolumab in Prostatic Neoplasms — 1 open to participants now, 9 under way, none of them phase 3. Nivolumab · Prostatic Neoplasms.
Among the 23 studies testing nivolumab in Prostatic Neoplasms, this one is the 2nd largest by enrollment, is one of 4 that started in 2020, is the only one in phase 3, and was the 17th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →1 of the 23 studies testing nivolumab in Prostatic Neoplasms is open now, in 2 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 18 · Phase 3 2
First in 2006; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,030 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 45 across the 23 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 23 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
30 studies in Prostatic Neoplasms by Bristol-Myers Squibb: 2 open now, 3 under way, 1 of them phase 3. Of 27 finished, 12 (44%) have results posted.
Among the 30 studies in Prostatic Neoplasms by Bristol-Myers Squibb, this one is the 3rd largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2020, is one of 6 in phase 3, and was the 25th registered.
Bristol-Myers Squibb’s Prostatic Neoplasms studies by the year they started, since 2002.
1 of the studies testing nivolumab in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03866382National Cancer Institute (NCI)Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing nivolumab in Prostatic Neoplasms, from their registry updates:
Among Bristol-Myers Squibb’s 30 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Nivolumab · Drug: Prednisone · Drug: Docetaxel
Drug: Prednisone · Drug: Docetaxel · Other: Placebo
Specified dose on specified days
Also known as: OPDIVO,, BMS-936558-01
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Radiographic Progressive Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group 3 (PCWG3)
rPFS for randomized participants is the time between randomization and the first date of documented progression or death due to any cause, whichever occurs first. The rPFS was censored at the last radiographic tumor assessment up to the start of subsequent cancer therapy for those without progression or death. It was also censored at the date of last radiographic tumor assessment prior to the missed tumor assessments for participants who had progressive disease (PD) or death immediately after more than one consecutive missed tumor assessments. Radiographic progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions is also considered progression.
Time frame: from randomization to the first date of documented progression or death due to any cause, whichever occurs first (up to approximately 31 months)
Overall Survival (OS)
OS for all randomized participants is the time between randomization and the date of death from any cause. For participants who are alive, their survival time was censored at the last date that they were known to be alive. OS was censored for participants at the date of randomization if they had no follow-up.
Time frame: From randomization to the date of death from any cause (Up to approximately 31 months)
Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)
Objective Response Rate per PCWG3 (ORR-PCWG3) is the percentage of participants who have a confirmed complete or partial best overall response (BOR) per PCWG3 among randomized participants who have measurable disease at baseline. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations.
Time frame: From date of randomization to the date of objectively documented progression per PCWG3 or the date of subsequent systemic cancer therapy, whichever occurs first (Up to approximately 52 months)
Time to Response (TTR) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)
Time to Response per PCWG3 (TTR-PCWG3) is the time from randomization to the date of the first documented CR or PR per PCWG3, as determined by BICR. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From randomization to the date of the first documented CR or PR (Up to approximately 52 months)
Duration of Response Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)
Duration of Response per PCWG3 (DOR-PCWG3) is time between the date of first response (CR/PR per PCWG3) to the date of first documented radiographic progression per PCWG3,as determined by BICR, or death due to any cause whichever occurs first. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Radiographic progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions is also considered progression.
Time frame: From randomization date to the date of first documented radiographic progression or death due to any cause whichever occurs first (Up to approximately 52 months)
Prostate-specific Antigen (PSA) Response Rate (PSA-RR)
PSA Response Rate (PSA-RR) is the percentage of randomized participants with a 50% or greater decrease in PSA from baseline to the lowest post-baseline PSA result. A second consecutive value obtained 3 or more weeks later is required to confirm the PSA response. Baseline was defined as valuations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations.
Time frame: Up to approximately 52 months
Time to PSA Progression (TTP-PSA)
Time to PSA Progression (TTP-PSA) is the time between randomization to the date of PSA progression per PCWG3 in randomized participants. PSA Progression: For participants with an initial PSA decline from baseline, the date of PSA progression is the date that an increase of 25% or more and an absolute increase of 2 ng/mL or more from the nadir are documented and confirmed by a second consecutive PSA value at least 3 weeks later. For participants with no PSA decline from baseline, the date of PSA progression is date that an increase of 25% or more and an absolute increase of 2 ng/mL or more from baseline are documented at or beyond Week 13. Baseline was defined as valuations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations. Censored at date of last PSA evaluation on/prior to start of subsequent cancer therapy.
Time frame: from randomization to the date of PSA Progression (Up to approximately 31 months)
Number of Participants With Adverse Events
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Time frame: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Number of Participants With Serious Adverse Events
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death or Is life-threatening or requires inpatient hospitalization or causes prolongation of existing hospitalization or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect.
Time frame: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Number of Participants With Adverse Events Leading to Discontinuation
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Time frame: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Number of Participants With Endocrine Immune-Mediated Adverse Events
Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Time frame: From first dose and 100 days after last dose of study therapy (Up to approximately 13 months)
Number of Participants With Non-Endocrine Immune-Mediated Adverse Events
Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Time frame: From first dose and 100 days after last dose of study therapy (Up to approximately 13 months)
Number of Participants With Select Adverse Events
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Time frame: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Number of Participants Who Died
Time frame: Up to approximately 52 months
Number of Participants With Worst Common Terminology Criteria (CTC) Grade Laboratory Test Grade Change From Baseline
The severity of laboratory test results were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0); Hematology parameters were evaluated for severity according to the following scale: Grade 0 is defined as absence of an AE or within normal limits; Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening. Number of participants with worst grade change results to Grade 3 or Grade 4 laboratory test results is presented. E.g., the row title HEMOGLOBIN Grade 0 to Grade 3, Grade 0 is baseline and Grade 3 is post baseline.
Time frame: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
Blood samples were collected for conducting specific thyroid test. Baseline is defined as evaluations or events that occur before the date and time of the first dose of study treatment. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations.
Time frame: From first dose and 30 days after last dose of study therapy (Up to approximately 11 months)
Time to Pain Progression as Assessed by Brief Pain Inventory-Short Form (BPI-SF)
The BPI-SF is an instrument to assess pain and includes severity and interference scores. BPI-SF is an 11-item self-report questionnaire designed to assess severity and impact of pain on daily function. Participants rate severity of pain at its "worst," "least," and "average" in last 24 hours using an 11-point numerical rating scale with anchors of "no pain" and "pain as bad. The participant's assessment of pain with BPI-SF Item number 3 (pain symptoms at their worst over the last 24 hours) form basis for analysis. Time to pain progression is time between date of randomization and date of first increase in worst pain intensity. Pain progression occurred if an increase in worst pain intensity of \>= 2 points is observed from baseline and maintained over 2 consecutive time periods. Baseline was evaluations or events that occur before date and time of first dose of study treatment or evaluations on same date and time of first dose of study treatment were also considered as baseline.
Time frame: From randomization to 1st pain symptoms at their worst over the last 24 hours (Up to approximately 31 months
| Milestone | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| Started | 514 | 516 |
| Completed | 510 | 510 |
| Not completed | 4 | 6 |
| Withdrew: Not reported | 0 | 4 |
| Withdrew: Subject no longer meets study criteria | 1 | 1 |
| Withdrew: Poor/non-compliance | 1 | 0 |
| Withdrew: Participant withdrew consent | 2 | 0 |
| Withdrew: Participant request to discontinue study treatment | 0 | 1 |
| Milestone | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| Started | 510 | 510 |
| Completed | 19 | 11 |
| Not completed | 491 | 499 |
| Withdrew: Ongoing treatment | 1 | 0 |
| Withdrew: Other reason | 26 | 37 |
| Withdrew: Completed treatment as per protocol | 1 | 2 |
| Withdrew: Maximum clinical benefit | 3 | 0 |
| Withdrew: Adverse event unrelated to study drug | 13 | 12 |
| Withdrew: Study drug toxicity | 67 | 28 |
| Withdrew: Disease progression | 284 | 327 |
| Withdrew: Administrative reasons by sponsor | 16 | 30 |
| Withdrew: Poor/non-compliance | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Death | 16 | 11 |
| Withdrew: Participant withdrew consent | 10 | 10 |
| Withdrew: Participant request to discontinue study treatment | 33 | 32 |
| Withdrew: Adverse event | 14 | 6 |
| Withdrew: Lack of efficacy | 4 | 2 |
rPFS for randomized participants is the time between randomization and the first date of documented progression or death due to any cause, whichever occurs first. The rPFS was censored at the last radiographic tumor assessment up to the start of subsequent cancer therapy for those without progression or death. It was also censored at the date of last radiographic tumor assessment prior to the missed tumor assessments for participants who had progressive disease (PD) or death immediately after more than one consecutive missed tumor assessments. Radiographic progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions is also considered progression.
| months | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| Radiographic Progressive Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group 3 (PCWG3) | 9.43 (8.48 to 10.32) | 8.74 (8.38 to 9.99) |
OS for all randomized participants is the time between randomization and the date of death from any cause. For participants who are alive, their survival time was censored at the last date that they were known to be alive. OS was censored for participants at the date of randomization if they had no follow-up.
| months | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| Overall Survival (OS) | 18.73 (16.95 to 21.03) | 18.92 (17.31 to 22.01) |
Objective Response Rate per PCWG3 (ORR-PCWG3) is the percentage of participants who have a confirmed complete or partial best overall response (BOR) per PCWG3 among randomized participants who have measurable disease at baseline. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations.
| percentage of participants | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3) | 27.3 (21.5 to 33.8) | 23.5 (17.9 to 30.0) |
Time to Response per PCWG3 (TTR-PCWG3) is the time from randomization to the date of the first documented CR or PR per PCWG3, as determined by BICR. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| months | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| Time to Response (TTR) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3) | 2.17 (1.4 to 7.8) | 2.20 (1.7 to 8.2) |
Duration of Response per PCWG3 (DOR-PCWG3) is time between the date of first response (CR/PR per PCWG3) to the date of first documented radiographic progression per PCWG3,as determined by BICR, or death due to any cause whichever occurs first. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Radiographic progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions is also considered progression.
| months | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| Duration of Response Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3) | 8.31 (6.18 to 10.15) | 8.11 (6.34 to 8.74) |
PSA Response Rate (PSA-RR) is the percentage of randomized participants with a 50% or greater decrease in PSA from baseline to the lowest post-baseline PSA result. A second consecutive value obtained 3 or more weeks later is required to confirm the PSA response. Baseline was defined as valuations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations.
| percentage of participants | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| Prostate-specific Antigen (PSA) Response Rate (PSA-RR) | 42.4 (38.0 to 46.8) | 41.6 (37.2 to 46.0) |
Time to PSA Progression (TTP-PSA) is the time between randomization to the date of PSA progression per PCWG3 in randomized participants. PSA Progression: For participants with an initial PSA decline from baseline, the date of PSA progression is the date that an increase of 25% or more and an absolute increase of 2 ng/mL or more from the nadir are documented and confirmed by a second consecutive PSA value at least 3 weeks later. For participants with no PSA decline from baseline, the date of PSA progression is date that an increase of 25% or more and an absolute increase of 2 ng/mL or more from baseline are documented at or beyond Week 13. Baseline was defined as valuations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations. Censored at date of last PSA evaluation on/prior to start of subsequent cancer therapy.
| months | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| Time to PSA Progression (TTP-PSA) | 6.28 (5.82 to 6.97) | 6.21 (5.65 to 6.77) |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
| Participants | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| Number of Participants With Adverse Events | 501 | 503 |
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death or Is life-threatening or requires inpatient hospitalization or causes prolongation of existing hospitalization or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect.
| Participants | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| Number of Participants With Serious Adverse Events | 223 | 192 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
| Participants | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| Number of Participants With Adverse Events Leading to Discontinuation | 148 | 101 |
Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
| Participants | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| Adrenal insufficiency | 7 | 4 |
| Hypothyroidism | 27 | 11 |
| Thyroiditis | 1 | 0 |
| Diabetes mellitus | 1 | 2 |
| Diabetic ketoacidosis | 1 | 0 |
| Type 1 diabetes mellitus | 1 | 0 |
| Hyperthyroidism | 20 | 11 |
| Immune-mediated hypophysitis | 1 | 0 |
| Hypopituitarism | 0 | 1 |
Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
| Participants | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| Pneumonitis | 15 | 2 |
| Interstitial lung disease | 5 | 1 |
| Immune-mediated lung disease | 1 | 0 |
| Diarrhoea | 8 | 2 |
| Colitis | 4 | 0 |
| Enterocolitis | 1 | 0 |
| Alanine aminotransferase increased | 5 | 0 |
| Aspartate aminotransferase increased | 3 | 0 |
| Hypertransaminasaemia | 3 | 0 |
| Autoimmune hepatitis | 2 | 0 |
| Immune-mediated hepatitis | 2 | 0 |
| Blood bilirubin increased | 1 | 0 |
| Cholangitis | 1 | 0 |
| Blood creatinine increased | 1 | 0 |
| Acute kidney injury | 0 | 1 |
| Immune-mediated nephritis | 0 | 1 |
| Rash | 14 | 7 |
| Rash maculo-papular | 3 | 0 |
| Rash pustular | 2 | 0 |
| Dermatitis | 1 | 1 |
| Dermatitis acneiform | 1 | 0 |
| Drug eruption | 1 | 0 |
| Pemphigoid | 1 | 0 |
| Erythema multiforme | 0 | 1 |
| Immune-mediated dermatitis | 0 | 1 |
| Rash macular | 0 | 1 |
| Infusion related reaction | 3 | 3 |
| Hypersensitivity | 0 | 1 |
| Infusion related hypersensitivity reaction | 0 | 1 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
| Participants | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| Diarrhoea | 176 | 159 |
| Colitis | 7 | 2 |
| Enterocolitis | 2 | 1 |
| Frequent bowel movements | 0 | 1 |
| Alanine aminotransferase increased | 36 | 14 |
| Aspartate aminotransferase increased | 26 | 15 |
| Blood alkaline phosphatase increased | 23 | 22 |
| Blood bilirubin increased | 8 | 4 |
| Gamma-glutamyltransferase increased | 5 | 3 |
| Hepatic cytolysis | 4 | 1 |
| Transaminases increased | 4 | 1 |
| Autoimmune hepatitis | 2 | 0 |
| Cholangitis | 2 | 0 |
| Hyperbilirubinaemia | 2 | 2 |
| Hypertransaminasaemia | 2 | 0 |
| Hepatic enzyme increased | 1 | 2 |
| Hepatitis | 1 | 0 |
| Immune-mediated hepatitis | 1 | 0 |
| Liver injury | 1 | 0 |
| Liver disorder | 0 | 1 |
| Pneumonitis | 26 | 6 |
| Interstitial lung disease | 7 | 4 |
| Acute respiratory failure | 1 | 0 |
| Immune-mediated lung disease | 1 | 0 |
| Lung infiltration | 1 | 0 |
| Idiopathic interstitial pneumonia | 0 | 1 |
| Blood creatinine increased | 22 | 7 |
| Acute kidney injury | 7 | 9 |
| Renal failure | 3 | 5 |
| Blood urea increased | 2 | 2 |
| Immune-mediated nephritis | 0 | 1 |
| Rash | 51 | 34 |
| Pruritus | 47 | 20 |
| Eczema | 10 | 3 |
| Rash maculo-papular | 11 | 6 |
| Dermatitis | 6 | 4 |
| Palmar-plantar erythrodysaesthesia syndrome | 5 | 22 |
| Urticaria | 5 | 3 |
| Erythema | 4 | 11 |
| Psoriasis | 4 | 3 |
| Skin exfoliation | 4 | 2 |
| Dermatitis acneiform | 3 | 1 |
| Rash macular | 3 | 2 |
| Dermatitis allergic | 2 | 0 |
| Rash erythematous | 2 | 2 |
| Rash pustular | 3 | 0 |
| Vitiligo | 2 | 1 |
| Blister | 1 | 0 |
| Dermatitis atopic | 1 | 2 |
| Dermatitis exfoliative | 1 | 0 |
| Drug eruption | 1 | 0 |
| Erythema multiforme | 1 | 1 |
| Exfoliative rash | 1 | 0 |
| Pemphigoid | 1 | 0 |
| Photosensitivity reaction | 1 | 0 |
| Rash papular | 1 | 1 |
| Rash pruritic | 1 | 0 |
| Immune-mediated dermatitis | 0 | 1 |
| Infusion related reaction | 22 | 27 |
| Hypersensitivity | 6 | 4 |
| Anaphylactic reaction | 1 | 0 |
| Anaphylactic shock | 1 | 0 |
| Bronchospasm | 0 | 1 |
| Infusion related hypersensitivity reaction | 0 | 3 |
| Participants | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| Number of Participants Who Died | 258 | 227 |
The severity of laboratory test results were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0); Hematology parameters were evaluated for severity according to the following scale: Grade 0 is defined as absence of an AE or within normal limits; Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening. Number of participants with worst grade change results to Grade 3 or Grade 4 laboratory test results is presented. E.g., the row title HEMOGLOBIN Grade 0 to Grade 3, Grade 0 is baseline and Grade 3 is post baseline.
| Participants | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| HEMOGLOBIN Grade 0 to Grade 3 | 5 | 3 |
| HEMOGLOBIN Grade 0 to Grade 4 | NA | NA |
| HEMOGLOBIN Grade 1 to Grade 3 | 20 | 16 |
| HEMOGLOBIN Grade 1 to Grade 4 | NA | NA |
| HEMOGLOBIN Grade 2 to Grade 3 | 11 | 11 |
| HEMOGLOBIN Grade 2 to Grade 4 | NA | NA |
| HEMOGLOBIN Grade 3 to Grade 3 | 0 | 0 |
| HEMOGLOBIN Grade 3 to Grade 4 | NA | NA |
| PLATELET COUNT Grade 0 to Grade 3 | 2 | 3 |
| PLATELET COUNT Grade 0 to Grade 4 | 0 | 1 |
| PLATELET COUNT Grade 1 to Grade 3 | 2 | 1 |
| PLATELET COUNT Grade 1 to Grade 4 | 1 | 1 |
| PLATELET COUNT Grade 2 to Grade 3 | 0 | 0 |
| PLATELET COUNT Grade 2 to Grade 4 | 0 | 0 |
| PLATELET COUNT Grade 3 to Grade 3 | 0 | 0 |
| PLATELET COUNT Grade 3 to Grade 4 | 0 | 0 |
| PLATELET COUNT Grade 4 to Grade 3 | 0 | 0 |
| PLATELET COUNT Grade 4 to Grade 4 | 0 | 0 |
| LEUKOCYTES Grade 0 to Grade 3 | 30 | 28 |
| LEUKOCYTES Grade 0 to Grade 4 | 11 | 13 |
| LEUKOCYTES Grade 1 to Grade 3 | 5 | 3 |
| LEUKOCYTES Grade 1 to Grade 4 | 1 | 1 |
| LEUKOCYTES Grade 2 to Grade 3 | 0 | 1 |
| LEUKOCYTES Grade 2 to Grade 4 | 0 | 0 |
| LEUKOCYTES Grade 3 to Grade 3 | 0 | 0 |
| LEUKOCYTES Grade 3 to Grade 4 | 0 | 0 |
| LEUKOCYTES Grade 4 to Grade 3 | 0 | 0 |
| LEUKOCYTES Grade 4 to Grade 4 | 0 | 0 |
| LYMPHOCYTES Grade 0 to Grade 3 | 22 | 17 |
| LYMPHOCYTES Grade 0 to Grade 4 | 1 | 1 |
| LYMPHOCYTES Grade 1 to Grade 3 | 24 | 22 |
| LYMPHOCYTES Grade 1 to Grade 4 | 3 | 1 |
| LYMPHOCYTES Grade 2 to Grade 3 | 19 | 30 |
| LYMPHOCYTES Grade 2 to Grade 4 | 2 | 2 |
| LYMPHOCYTES Grade 3 to Grade 3 | 10 | 19 |
| LYMPHOCYTES Grade 3 to Grade 4 | 2 | 4 |
| LYMPHOCYTES Grade 4 to Grade 3 | 0 | 0 |
| LYMPHOCYTES Grade 4 to Grade 4 | 0 | 0 |
| ANC Grade 0 to Grade 3 | 18 | 16 |
| ANC Grade 0 to Grade 4 | 44 | 39 |
| ANC Grade 1 to Grade 3 | 0 | 0 |
| ANC Grade 1 to Grade 4 | 0 | 1 |
| ANC Grade 2 to Grade 3 | 0 | 1 |
| ANC Grade 2 to Grade 4 | 0 | 1 |
| ANC Grade 3 to Grade 3 | 0 | 0 |
| ANC Grade 3 to Grade 4 | 0 | 0 |
| ANC Grade 4 to Grade 3 | 0 | 0 |
| ANC Grade 4 to Grade 4 | 0 | 0 |
| ALP Grade 0 to Grade 3 | 5 | 1 |
| ALP Grade 0 to Grade 4 | 0 | 0 |
| ALP Grade 1 to Grade 3 | 1 | 1 |
| ALP Grade 1 to Grade 4 | 0 | 0 |
| ALP Grade 2 to Grade 3 | 0 | 0 |
| ALP Grade 2 to Grade 4 | 0 | 0 |
| ALP Grade 3 to Grade 4 | 0 | 0 |
| ALP Grade 4 to Grade 3 | 0 | 0 |
| ALP Grade 4 to Grade 4 | 0 | 0 |
| AMT Grade 0 to Grade 3 | 6 | 0 |
| AMT Grade 0 to Grade 4 | 1 | 0 |
| AMT Grade 1 to Grade 3 | 1 | 2 |
| AMT Grade 1 to Grade 4 | 1 | 1 |
| AMT Grade 2 to Grade 3 | 0 | 0 |
| AMT Grade 2 to Grade 4 | 0 | 0 |
| AMT Grade 3 to Grade 3 | 0 | 0 |
| AMT Grade 3 to Grade 4 | 0 | 0 |
| AMT Grade 4 to Grade 3 | 0 | 0 |
| AMT Grade 4 to Grade 4 | 0 | 0 |
| ALT Grade 0 to Grade 3 | 7 | 2 |
| ALT Grade 0 to Grade 4 | 3 | 0 |
| ALT Grade 1 to Grade 3 | 0 | 0 |
| ALT Grade 1 to Grade 4 | 0 | 0 |
| ALT Grade 2 to Grade 3 | 0 | 0 |
| ALT Grade 3 to Grade 3 | 0 | 0 |
| ALT Grade 4 to Grade 3 | 0 | 0 |
| ALT Grade 4 to Grade 4 | 0 | 0 |
| BILIRUBIN Grade 0 to Grade 3 | 2 | 1 |
| BILIRUBIN Grade 0 to Grade 4 | 1 | 0 |
| BILIRUBIN Grade 1 to Grade 3 | 0 | 0 |
| BILIRUBIN Grade 1 to Grade 4 | 0 | 0 |
| BILIRUBIN Grade 2 to Grade 3 | 0 | 0 |
| BILIRUBIN Grade 2 to Grade 4 | 0 | 0 |
| BILIRUBIN Grade 3 to Grade 3 | 0 | 0 |
| BILIRUBIN Grade 3 to Grade 4 | 0 | 0 |
| BILIRUBIN Grade 4 to Grade 3 | 0 | 0 |
| BILIRUBIN Grade 4 to Grade 4 | 0 | 0 |
| CREATININE Grade 0 to Grade 3 | 4 | 4 |
| CREATININE Grade 0 to Grade 4 | 0 | 0 |
| CREATININE Grade 1 to Grade 3 | 1 | 0 |
| CREATININE Grade 1 to Grade 4 | 1 | 0 |
| CREATININE Grade 2 to Grade 3 | 0 | 1 |
| CREATININE Grade 2 to Grade 4 | 1 | 0 |
| CREATININE Grade 3 to Grade 3 | 0 | 0 |
| CREATININE Grade 3 to Grade 4 | 0 | 0 |
| CREATININE Grade 4 to Grade 3 | 0 | 0 |
| CREATININE Grade 4 to Grade 4 | 0 | 0 |
| HYPERNATREMIA Grade 0 to Grade 3 | 0 | 0 |
| HYPERNATREMIA Grade 0 to Grade 4 | 0 | 0 |
| HYPERNATREMIA Grade 1 to Grade 3 | 0 | 0 |
| HYPERNATREMIA Grade 1 to Grade 4 | 0 | 0 |
| HYPERNATREMIA Grade 2 to Grade 3 | 0 | 0 |
| HYPERNATREMIA Grade 2 to Grade 4 | 0 | 0 |
| HYPERNATREMIA Grade 3 to Grade 3 | 0 | 0 |
| HYPERNATREMIA Grade 3 to Grade 4 | 0 | 0 |
| HYPERNATREMIA Grade 4 to Grade 3 | 0 | 0 |
| HYPERNATREMIA Grade 4 to Grade 4 | 0 | 0 |
| HYPONATREMIA Grade 0 to Grade 3 | 5 | 4 |
| HYPONATREMIA Grade 0 to Grade 4 | 0 | 1 |
| HYPONATREMIA Grade 1 to Grade 3 | 0 | 0 |
| HYPONATREMIA Grade 1 to Grade 4 | 0 | 1 |
| HYPONATREMIA Grade 2 to Grade 3 | 0 | 0 |
| HYPONATREMIA Grade 2 to Grade 4 | 0 | 0 |
| HYPONATREMIA Grade 3 to Grade 3 | 0 | 0 |
| HYPONATREMIA Grade 3 to Grade 4 | 0 | 0 |
| HYPONATREMIA Grade 4 to Grade 3 | 0 | 0 |
| HYPONATREMIA Grade 4 to Grade 4 | 0 | 0 |
| HYPERKALEMIA Grade 0 to Grade 3 | 8 | 1 |
| HYPERKALEMIA Grade 0 to Grade 4 | 2 | 1 |
| HYPERKALEMIA Grade 1 to Grade 3 | 2 | 0 |
| HYPERKALEMIA Grade 1 to Grade 4 | 0 | 1 |
| HYPERKALEMIA Grade 2 to Grade 3 | 1 | 0 |
| HYPERKALEMIA Grade 2 to Grade 4 | 0 | 0 |
| HYPERKALEMIA Grade 3 to Grade 3 | 0 | 0 |
| HYPERKALEMIA Grade 3 to Grade 4 | 0 | 0 |
| HYPERKALEMIA Grade 4 to Grade 3 | 0 | 0 |
| HYPERKALEMIA Grade 4 to Grade 4 | 0 | 0 |
| HYPOKALEMIA Grade 0 to Grade 3 | 7 | 8 |
| HYPOKALEMIA Grade 0 to Grade 4 | 1 | 0 |
| HYPOKALEMIA Grade 1 to Grade 3 | 3 | 1 |
| HYPOKALEMIA Grade 1 to Grade 4 | 0 | 0 |
| HYPOKALEMIA Grade 2 to Grade 3 | 0 | 0 |
| HYPOKALEMIA Grade 2 to Grade 4 | 0 | 0 |
| HYPOKALEMIA Grade 3 to Grade 3 | 0 | 0 |
| HYPOKALEMIA Grade 3 to Grade 4 | 0 | 0 |
| HYPOKALEMIA Grade 4 to Grade 3 | 0 | 0 |
| HYPOKALEMIA Grade 4 to Grade 4 | 0 | 0 |
| HYPERCALCEMIA Grade 0 to Grade 3 | 0 | 0 |
| HYPERCALCEMIA Grade 0 to Grade 4 | 0 | 0 |
| HYPERCALCEMIA Grade 1 to Grade 3 | 0 | 0 |
| HYPERCALCEMIA Grade 1 to Grade 4 | 1 | 0 |
| HYPERCALCEMIA Grade 2 to Grade 3 | 0 | 0 |
| HYPERCALCEMIA Grade 2 to Grade 4 | 0 | 0 |
| HYPERCALCEMIA Grade 3 to Grade 3 | 0 | 0 |
| HYPERCALCEMIA Grade 3 to Grade 4 | 0 | 0 |
| HYPERCALCEMIA Grade 4 to Grade 3 | 0 | 0 |
| HYPERCALCEMIA Grade 4 to Grade 4 | 0 | 0 |
| HYPOCALCEMIA Grade 0 to Grade 3 | 6 | 4 |
| HYPOCALCEMIA Grade 0 to Grade 4 | 1 | 0 |
| HYPOCALCEMIA Grade 1 to Grade 3 | 1 | 2 |
| HYPOCALCEMIA Grade 1 to Grade 4 | 0 | 0 |
| HYPOCALCEMIA Grade 2 to Grade 3 | 3 | 0 |
| HYPOCALCEMIA Grade 2 to Grade 4 | 3 | 0 |
| HYPOCALCEMIA Grade 3 to Grade 3 | 0 | 0 |
| HYPOCALCEMIA Grade 3 to Grade 4 | 0 | 0 |
| HYPOCALCEMIA Grade 4 to Grade 3 | 0 | 0 |
| HYPOCALCEMIA Grade 4 to Grade 4 | 0 | 0 |
| HYPERMAGNESEMIA Grade 0 to Grade 3 | 4 | 3 |
| HYPERMAGNESEMIA Grade 0 to Grade 4 | 0 | 0 |
| HYPERMAGNESEMIA Grade 1 to Grade 3 | 1 | 0 |
| HYPERMAGNESEMIA Grade 1 to Grade 4 | 0 | 0 |
| HYPERMAGNESEMIA Grade 2 to Grade 3 | 0 | 0 |
| HYPERMAGNESEMIA Grade 2 to Grade 4 | 0 | 0 |
| HYPERMAGNESEMIA Grade 3 to Grade 3 | 1 | 0 |
| HYPERMAGNESEMIA Grade 3 to Grade 4 | 0 | 0 |
| HYPERMAGNESEMIA Grade 4 to Grade 3 | 0 | 0 |
| HYPERMAGNESEMIA Grade 4 to Grade 4 | 0 | 0 |
| HYPOMAGNESEMIA Grade 0 to Grade 3 | 0 | 0 |
| HYPOMAGNESEMIA Grade 0 to Grade 4 | 0 | 0 |
| HYPOMAGNESEMIA Grade 1 to Grade 3 | 0 | 0 |
| HYPOMAGNESEMIA Grade 1 to Grade 4 | 0 | 0 |
| HYPOMAGNESEMIA Grade 2 to Grade 3 | 0 | 0 |
| HYPOMAGNESEMIA Grade 2 to Grade 4 | 0 | 0 |
| HYPOMAGNESEMIA Grade 3 to Grade 3 | 0 | 0 |
| HYPOMAGNESEMIA Grade 3 to Grade 4 | 0 | 0 |
| HYPOMAGNESEMIA Grade 4 to Grade 3 | 0 | 0 |
| HYPOMAGNESEMIA Grade 4 to Grade 4 | 0 | 0 |
| HYPOGLYCEMIA Grade 0 to Grade 3 | 1 | 1 |
| HYPOGLYCEMIA Grade 0 to Grade 4 | 1 | 0 |
| HYPOGLYCEMIA Grade 1 to Grade 3 | 0 | 0 |
| HYPOGLYCEMIA Grade 1 to Grade 4 | 0 | 0 |
| HYPOGLYCEMIA Grade 2 to Grade 3 | 0 | 0 |
| HYPOGLYCEMIA Grade 2 to Grade 4 | 0 | 0 |
| HYPOGLYCEMIA Grade 3 to Grade 3 | 0 | 0 |
| HYPOGLYCEMIA Grade 3 to Grade 4 | 0 | 0 |
| HYPOGLYCEMIA Grade 4 to Grade 3 | 0 | 0 |
| HYPOGLYCEMIA Grade 4 to Grade 4 | 0 | 0 |
Blood samples were collected for conducting specific thyroid test. Baseline is defined as evaluations or events that occur before the date and time of the first dose of study treatment. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations.
| Participants | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| TSH > (Upper Limit of Normal) ULN | 94 | 77 |
| TSH > ULN with TSH <= Upper limit of Normal (ULN) AT Baseline | 79 | 54 |
| TSH > ULN with at Least One FT3/FT4 Test Value < LLN | 39 | 20 |
| TSH > ULN With All Other FT3/FT4 Test Values >= LLN | 65 | 52 |
| TSH > ULN with FT3/FT4 Test Missing | 22 | 23 |
| TSH < Lower Limit of Normal (LLN) | 155 | 124 |
| TSH < LLN with TSH >= LLN at Baseline | 126 | 98 |
| TSH < LLN with at Least One FT3/FT4 Test Value > ULN | 33 | 14 |
| TSH < LLN with all other FT3/FT4 Test Values <= ULN | 116 | 106 |
| TSH < LLN with FT3/FT4 Test Missing | 45 | 24 |
The BPI-SF is an instrument to assess pain and includes severity and interference scores. BPI-SF is an 11-item self-report questionnaire designed to assess severity and impact of pain on daily function. Participants rate severity of pain at its "worst," "least," and "average" in last 24 hours using an 11-point numerical rating scale with anchors of "no pain" and "pain as bad. The participant's assessment of pain with BPI-SF Item number 3 (pain symptoms at their worst over the last 24 hours) form basis for analysis. Time to pain progression is time between date of randomization and date of first increase in worst pain intensity. Pain progression occurred if an increase in worst pain intensity of \>= 2 points is observed from baseline and maintained over 2 consecutive time periods. Baseline was evaluations or events that occur before date and time of first dose of study treatment or evaluations on same date and time of first dose of study treatment were also considered as baseline.
| months | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| Time to Pain Progression as Assessed by Brief Pain Inventory-Short Form (BPI-SF) | 11.53 (10.28 to 13.57) | 12.42 (11.07 to 13.63) |
Collected over All cause mortality was collected from randomization till death (up to approximately 52 months), Serious adverse events and non-serious adverse events were collected from first dose till 100 days post last dose (Up to approximately 27 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nivolumab + Docetaxel + Prednisone | 259/514 (50.4%) | 256/510 (50.2%) | 479/510 (93.9%) |
| Placebo + Docetaxel + Prednisone | 227/516 (44%) | 242/510 (47.5%) | 494/510 (96.9%) |
| Event | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 19/510 | 27/510 |
| PneumoniaInfections and infestations | 18/510 | 8/510 |
| Febrile neutropeniaBlood and lymphatic system disorders | 17/510 | 14/510 |
| COVID-19Infections and infestations | 11/510 | 13/510 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 10/510 | 13/510 |
| HaematuriaRenal and urinary disorders | 13/510 | 2/510 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 13/510 | 3/510 |
| AnaemiaBlood and lymphatic system disorders | 6/510 | 12/510 |
| DiarrhoeaGastrointestinal disorders | 12/510 | 9/510 |
| NeutropeniaBlood and lymphatic system disorders | 9/510 | 10/510 |
| Event | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone |
|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 172/510 | 178/510 |
| DiarrhoeaGastrointestinal disorders | 175/510 | 162/510 |
| AnaemiaBlood and lymphatic system disorders | 157/510 | 165/510 |
| FatigueGeneral disorders | 141/510 | 149/510 |
| NauseaGastrointestinal disorders | 108/510 | 134/510 |
| AstheniaGeneral disorders | 113/510 | 108/510 |
| ConstipationGastrointestinal disorders | 112/510 | 101/510 |
| Oedema peripheralGeneral disorders | 90/510 | 108/510 |
| Decreased appetiteMetabolism and nutrition disorders | 96/510 | 97/510 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 84/510 | 97/510 |
| Age, Continuous(years) | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone | Total |
|---|---|---|---|
| Mean | 68.9 ± 7.5 | 69.6 ± 8.1 | 69.2 ± 7.8 |
| Sex: Female, Male(Participants) | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone | Total |
|---|---|---|---|
| Female | 0 | 1 | 1 |
| Male | 514 | 515 | 1029 |
| Race/Ethnicity, Customized(participants) | Nivolumab + Docetaxel + Prednisone | Placebo + Docetaxel + Prednisone | Total |
|---|---|---|---|
| White | 333 | 329 | 662 |
| Black or African American | 20 | 15 | 35 |
| Asian | 35 | 45 | 80 |
| Native Hawaiian or other pacific islander | 1 | 0 | 1 |
| Chinese | 40 | 38 | 78 |
| Japanese | 33 | 45 | 78 |
| Asian other | 1 | 0 | 1 |
| Other | 30 | 27 | 57 |
| Not Reported | 19 | 16 | 35 |
| Asian Indian | 2 | 1 | 3 |
Showing the first 100 of 293 sites across 28 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2020 to primary completion in Jun 2023, 39 months.
Results were first posted in Jul 2024, 1 year 1 month after primary completion.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 39 months is close to that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab